Showing 2581-2590 of 9110 results for "".
DWTV Extra: Phase 3 Data on Roflumilast for AD, PsO
https://practicaldermatology.com/videos/dermwire-tv/dwtv-extra-phase-3-data-on-roflumilast-for-ad-pso/35925/Study investigator Melinda Gooderham, MD, talks about the Phase 3 trials of roflumilast cream 0.15% for adults and children down to age 6 with atopic dermatitis and roflumilast foam 0.3% for patients older than 12 with psoriasis of the scalp and body.Study Examines Socioeconomic Status and HS Diagnosis
https://practicaldermatology.com/videos/dermwire-tv/study-examines-socioeconomic-status-and-hs-diagnosis/35859/In this week's DermwireTV, a new study examines the association between socioeconomic status and HS diagnosis; a new meta-analysis highlights the therapeutic potential of simvastatin for vitiligo; and in our “Updates on Skin Cancer” feature, we hear about how to use gene expression profile testing fEvaluating GEP Test Options
https://practicaldermatology.com/programs/practical-dermatology/evaluating-gep-test-options/35600/David Cotter, MD, a board-certified dermatologist, discusses what he looks for in a gene expression profile (GEP) test, including the types of clinical evidence that are most important.Dupilumab's Impact on Height, 40-GEP for HNcSCC Lead Posters at Maui Derm
https://practicaldermatology.com/programs/practical-dermatology/dupilumabs-impact-on-height-40-gep-for-hncscc-lead-posters-at-maui-derm/32916/The impact of dupilumab on children’s height and the 40-gene expression profile (40-GEP) test for patients with cutaneous squamous cell carcinoma of the head and neck (HNcSCC) were the topics of the top two posters in the “Late Breakers 2025” session at Maui Derm 2025 in Maui, Hawaii.Acne and Rosacea: Dr. Baldwin
https://practicaldermatology.com/conferences/maui-derm-hawaii-2025/acne-and-rosacea-dr-baldwin/32693/Hilary Baldwin, MD, talks about a topic that she did not have time to cover during "Update 2025: Acne and Rosacea" at Maui Derm 2025—emergency contraception in patients on isotretinoin.DermwireTV 2024 Year in Review
https://practicaldermatology.com/videos/dermwire-tv/dermwiretv-2024-year-in-review/32206/We look back at the top stories of 2024 in the Dermatology and Aesthetics markets. Several new products were approved or launched in atopic dermatitis, rosacea, prurigo nodularis, and hidradenitis suppurativa; new clinical guidelines were made for AD, acne care, and skin cancer; and a new study raisImproving the After-Sun Treatment Market
https://practicaldermatology.com/videos/c-suite-chats/improving-after-sun-treatment-market/29805/Ed Esquenazi, PhD, Founder and CEO of health and performance company, Terns, discusses the after-sun treatment market and two new products designed to combat inflammation and aging after exposure to the sun.SDPA: Dr. Audrey Rutherford Shares How Vulvovaginal Dermatology Became Her Specialty
https://practicaldermatology.com/conferences/sdpa-2024/sdpa-dr-audrey-rutherford-shares-how-vulvovaginal-dermatology-became-her-specialty/29511/At the SDPA 22nd Annual Fall Dermatology Conference, Practical Dermatology caught up with Audrey Rutherford, MD. Dr. Rutherford shares how she got started in vulvovaginal dermatology and key takeaways from her lecture.FDA Approves Axillary Hyperhidrosis Treatment; Study Examines Biologic Outcomes in Psoriasis
https://practicaldermatology.com/series/dermwire-tv/fda-approves-axillary-hyperhidrosis-treatment-study-examines-biologic-outcomes-psoriasis/26562/In this week's DermwireTV, the FDA approves a first-of-its-kind gel for axillary hyperhidrosis; a new analysis examines how smoking, BMI, and age affect biologic outcomes in psoriasis; and the CEO of Aerolase joins us to discuss the latest trends in the aesthetic laser market.DermWireTV: Diagnosing Melanoma Using Deep-Learning Model; New Adbry Approval
https://practicaldermatology.com/videos/dermwire-tv/dermwiretv-diagnosing-melanoma-using-deep-learning-model-new-adbry-approval/26445/In this week's DermWireTV, researchers develop a novel deep-learning model designed to more accurately diagnose melanoma; LEO Pharma receives a new approval for atopic dermatitis drug Adbry; and in our PA Perspectives segment, Andrew Mastro discusses how to build an inflammatory clinic.